Skip to content
ClearheadLab
Explore

A calm evidence note

Does Ozempic Cause Brain Fog?

Brain fog isn't a labeled Ozempic side effect. When it happens it's usually from eating too little, dehydration, or low blood sugar — the honest evidence.

Written with care by Nadia BrooksUpdated
On this page

Our clearest pick

CoreAge Rx

From $93/mo

NAD+ nasal spray or injection advertised from $93/month, with online clinical review.

Check availability
Form
Nasal spray + injection
Pricing
Varies by plan
Review
Clinician-reviewed intake
Pharmacy
Not named

Advertising disclosure · we may earn a commission if you start through this link, at no extra cost to you. This is a note on provider value, not a promise about focus, and what we write about the product is the same either way.

Also compared

HealthRX

From $134/mo

Publishes its whole price ladder in the open — both routes, with the provider visit, the supplies and the shipping already inside the figure.

See all 61 providers compared

If you have felt slow or hazy since starting Ozempic, Wegovy, or another GLP-1 medication, note when it started. It can help to review changes in dose, food and fluid intake, and other medications with your prescriber.

First, the honest framing: it's not a labeled drug effect

The Ozempic prescribing information lists nausea and constipation among the common adverse reactions. It does not list brain fog among them11. And when researchers have looked at the broader question of how GLP-1 drugs affect the brain and mind, the signal does not point toward harm. A systematic review and meta-analysis of GLP-1 receptor agonists and neuropsychiatric outcomes found no consistent evidence that the class worsens cognition or mood at the group level1. So the starting point is not "Ozempic damages your thinking." It is: a foggy head on a GLP-1 is real and worth explaining, but the explanation usually lies in the consequences of the drug working — you eat far less, you may drink less, and your blood sugar shifts — not in a direct neurological action.

Why fog happens on a GLP-1

GLP-1 blunts appetite

Eat far less; slowed stomach emptying; GI side effects

Under-eating, dehydration, low blood sugar

Each a known cause of foggy thinking

Experienced as brain fog

Fixable by addressing intake, fluids, and glucose

If fog starts while taking a GLP-1 medication, check for changes in food and fluid intake and discuss whether low blood sugar is possible.

The real culprits: eating less, drinking less, lower blood sugar

GLP-1 drugs work largely by blunting appetite — quieting the constant chatter about food people call food noise — and slowing how fast the stomach empties, so people on them eat substantially less. That sharp drop in intake is the most likely engine behind GLP-1-associated fog, through three overlapping routes.

Under-eating and very low calorie intake. When appetite falls off a cliff, many people end up eating far below their needs — sometimes skipping meals entirely without noticing. The brain runs on a steady fuel supply, and abrupt, large caloric restriction can come with fatigue, irritability, and reduced mental sharpness, particularly in the early adjustment period. Controlled diet research shows the early phase of a hypocaloric, carbohydrate-restricted diet can transiently affect mood and cognitive performance before the body adapts2, and analyzes of caloric restriction and cognition show the relationship is real but modest and context-dependent3. The practical version: if you have unintentionally cut your intake to very little, foggy, low-energy thinking is an expected consequence — of the eating pattern, not the drug's chemistry.

Dehydration. This one is underrated. GLP-1 side effects — nausea, vomiting, diarrhea, and simply drinking less because you feel full — push many people toward mild dehydration, and mild dehydration is itself a well-documented cause of fog. A fluid deficit of just 1–2% of body weight measurably blunts attention and worsens mood and fatigue, often before you feel thirsty45. So a foggy head on a GLP-1 is frequently a hydration problem wearing a drug-side-effect costume — which is good news, because it is the easiest thing to fix. We cover the threshold and the fix in depth in dehydration brain fog.

Low blood sugar. The risk is higher when semaglutide is taken with insulin or a sulfonylurea11. If symptoms include sweating, shaking or confusion, check glucose if you can and follow your care plan. A glucose reading is more informative than the sensation alone. Our guide to diabetes and brain fog explains why both highs and lows can matter.

What the evidence supports

  • Direct "Ozempic fogs your brain" effectNo evidence

    Not a labeled adverse effect; meta-analysis shows no consistent cognitive/mood harm at the group level.

  • Indirect fog from under-eating, dehydration, low blood sugarModerate evidence

    Well-supported mechanistically by diet, hydration, and hypoglycemia research.

  • GLP-1 drugs protect the brain long-termWeak evidence

    Plausible and still studied, but the dedicated EVOKE Alzheimer's trial was negative on slowing decline.

The prescribing information and group-level studies cannot identify what is causing symptoms for an individual.

There is also a low-carbohydrate angle that overlaps with all three: people on GLP-1 drugs often gravitate toward smaller, protein-focused meals and away from carbohydrates, and the early adaptation to a markedly lower-carb intake can itself bring a transient "keto-flu"-style dip in mental sharpness and mood before the body adjusts2. None of these mechanisms requires the drug to be doing anything toxic to neurons — they are downstream of dramatically changed eating and drinking.

What about the long term — isn't Ozempic supposed to be good for the brain?

This is where the honest framing cuts both ways, because the long-term story is genuinely interesting but has just delivered a sobering result. There is a real and active body of research into whether GLP-1 drugs might protect the brain. Preclinical and mechanistic work shows GLP-1 receptor agonists can reduce neuroinflammation and influence Alzheimer's-related pathways7, systematic reviews catalog plausible effects on Alzheimer's pathophysiology8, and the class has been explored across Alzheimer's and Parkinson's disease for exactly this reason9. That made GLP-1 drugs a leading hope for neuroprotection.

But hope is not proof — and here the evidence demands honesty. The first large, dedicated randomized trials of a GLP-1 drug for early Alzheimer's disease (the EVOKE and EVOKE+ studies of oral semaglutide) reported in 2025 that the drug did not slow cognitive or functional decline on the primary endpoint10. In other words, the most direct test of the "Ozempic protects the brain" idea was negative for Alzheimer's progression. So the accurate statement is: the long-term neuroprotection hypothesis is biologically plausible and still being studied for other questions, but it is not established, and the headline Alzheimer's trial failed. Anyone telling you Ozempic is a proven brain-booster is ahead of the evidence — and so is anyone telling you it rots your brain.

How to tell which kind of fog you have

Keep a short record of when the fog happens, dose changes, meals, and any vomiting or diarrhea. If you monitor glucose, include readings taken during symptoms. Bring the record to your prescriber before changing the dose.

If fatigue is the main change you notice, our guide to GLP-1 fatigue covers what to record before speaking with the prescriber. For symptoms that began before the medication or do not fit this pattern, see other causes of brain fog.

The bottom line

Brain fog is not listed among the common adverse reactions in the Ozempic prescribing information, and the broad evidence does not show these drugs worsen cognition at the group level1. When fog does appear on a GLP-1, several factors are worth checking, including eating too little23, dehydration from reduced intake and GI side effects45, or low or unstable blood sugar6 — all of which are identifiable and fixable. The long-term hope that GLP-1 drugs protect the brain is biologically plausible and still under study789, but it is not proven — and the first dedicated Alzheimer's trial of semaglutide was negative on slowing decline10. The honest takeaway: don't blame the molecule, and don't credit it with more than the evidence supports — check your food, fluids, and blood sugar first, and loop in your prescriber if the fog is severe.

GLP-1 / weight-loss telehealth — adjacent options

A separate metabolic-health path — not a brain-fog fix

Clearhead Lab is about brain fog, focus, and cognitive energy — our primary pick there is prescription NAD+ from CoreAge Rx, and nothing below changes that. But if you landed here because you're on — or weighing — a GLP-1 for weight, the telehealth options below sit in that separate lane. To be clear: starting a GLP-1 is a metabolic-health decision made with a prescriber, not a treatment for brain fog. If anything, the fog people report on these drugs is usually downstream of eating and drinking less (covered above) — not something a new prescription resolves.

Direct Meds

Compounded GLP-1 · sublingual + injectable

A telehealth operator (launched 2024) offering compounded semaglutide and tirzepatide in both sublingual and injectable forms after an online medical review.

Pricing: Roughly $179–$399/month, per the company's own stated pricing (not independently verified).

Worth knowing: Compounded, not FDA-approved products; pricing is company-stated and can change; the brand operates across multiple domains, which can make it harder to know exactly who you're buying from.

FDA warning letter to directmeds.com, Inc. dba DirectMeds, September 2025. It concerns its compounded GLP-1 line — the same products this card is about. Look it up in the FDA warning-letter database

Gala Health

Compounded & brand GLP-1 · all 50 states

A newer telehealth operator prescribing compounded tirzepatide and semaglutide, plus brand-name options, with nationwide (all-50-state) availability.

Pricing: Company-stated: compounded tirzepatide from $179/month, a microdose tier around $149, a 3-month plan near $199; brand-name Ozempic listed around $1,299. No oral option yet.

Worth knowing: Most tiers are compounded, not FDA-approved; it's a newer operator with a shorter track record; no oral/tablet route is offered.

Enhance MD

Compounded GLP-1 · injectable + NAD+

A compounded-GLP-1 telehealth practice offering injectable semaglutide and tirzepatide — including microdose and a combo tier — with provider support and metabolic lab work, plus NAD+ injections on the side.

Pricing: Company-stated: compounded semaglutide $212/month (first month $112 on a promo), tirzepatide $280/month, a microdose tier at $169/month, and a sema+tirz combo at $322/month. Dosing is flat within a tier. No brand-name or oral option.

Worth knowing: Compounded, not FDA-approved products; no brand-name or oral/tablet route; the number of states served isn't published; entry pricing runs higher than budget compounders.

HealthRX

Compounded GLP-1 · injectable + oral tablet

A LegitScript-certified (#50087439), physician-supervised telehealth practice for medical weight loss, prescribing compounded semaglutide and tirzepatide plus an oral GLP tablet after an online medical review — with transparent pricing and no insurance required.

Pricing: Company-stated: injectable from around $189/month, an oral GLP tablet near $239/month, and a GLP+GIP tier around $349/month. No insurance is billed.

Worth knowing: Compounded medications are not FDA-approved; some tiers are company-stated and the site is thin in places; the number of states served isn't published.

RxSpan MD

Compounded + brand-name & microdose GLP-1 · physician-led

A physician-led telehealth practice founded by Dr. John Diaz, a board-certified plastic surgeon, with a broad menu: injectable compounded semaglutide and tirzepatide, an advertised brand-name GLP-1 lane, and microdosing — alongside longevity, hair-loss, and sexual-health lines. Includes 24/7 messaging, coaching, and free expedited shipping.

Pricing: From $194/mo. Compounded semaglutide runs $249/month or drops to $194/month on the annual plan; tirzepatide starts at $329 and semaglutide oral capsules at $249 for the first month. Pricing is all-inclusive of the consult, medication, supplies, and shipping.

Worth knowing: Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Ozempic/Wegovy/Zepbound); the published pricing covers the compounded line, and brand-name pricing isn't itemized; a prescription isn't guaranteed — a provider reviews your eligibility after checkout.

yourEra

Compounded GLP-1 · injectable · + NAD+ & microdosing

A telehealth practice pairing compounded, weekly-injectable semaglutide and tirzepatide with a longevity menu — NAD+ and a low-dose 'mood and momentum' microdosing protocol — plus an optional membership adding 1:1 coaching, a nutritionist, at-home lab draws, and wearables. Pricing is listed openly on the site, and no insurance is required.

Pricing: Company-stated: compounded semaglutide from $199/month and tirzepatide from $299/month (both weekly injectable), NAD+ from $170/month, and microdosing from $179/month; an optional yourEra Optimum membership adds about $149/month. HSA/FSA accepted; no insurance billed.

Worth knowing: Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Ozempic/Wegovy/Zepbound), and compounding availability can tighten as brand shortages ease; pricing sits mid-market — above the cheapest compounders; injectable-only, with no brand-name or oral route; the independent footprint is thin and the 50-state and efficacy claims are self-reported.

Sprout Health

Compounded & brand GLP-1 · low-friction start

LegitScript-certified GLP-1 telehealth offering compounded semaglutide and tirzepatide alongside a real brand-name Wegovy and Zepbound path, with a low-friction start that often skips labs and the video visit.

Pricing: Company-stated: compounded semaglutide from $149/mo, tirzepatide from $199/mo; brand-name Wegovy/Zepbound available at brand pricing.

Worth knowing: Compounded products are not FDA-approved and injectable-only (no oral). No named medical director, and state availability is quiz-gated.

FDA warning letter to Sprout Health Partners LLC dba Sprout Health, September 2025. It concerns its compounded GLP-1 line — the letter does not mention NAD+. Look it up in the FDA warning-letter database

Shed

Compounded & brand GLP-1 · widest format menu

A care-team GLP-1 program (physician, nurse, dietitian, coach) run by Shed Holdings, LLC, with one of the widest format menus — compounded semaglutide/tirzepatide injections plus GLP-1 drops, lozenges and a microdose option, alongside brand-name Wegovy, Zepbound and Foundayo routes.

Pricing: Read off the product pages: compounded semaglutide is $199/mo month to month ($179 on six months, $159 on twelve); tirzepatide is $299/mo ($269 / $239). The $159 and $239 figures on Shed's own banner are the twelve-month commitment rungs, not monthly rates. Brand-name Wegovy and Foundayo start at $149–$199 for the medication plus a separate Shed membership, stated as $125/mo in the page hero and $99 in the same page's FAQ.

Worth knowing: Compounded drops/lozenge/microdose formats are not FDA-evaluated in those delivery forms. Every program carries a two-month minimum term, stated only in the terms; prices step up with dose; and the advertised 120-day guarantee requires four monthly coaching appointments, twice-monthly weigh-ins and half the daily app check-ins, and is void if you have used the medication class before.

Sesame Care

Cash-pay clinician marketplace · GLP-1 prescriptions

Not a clinic — a two-sided marketplace that sells appointments. Independent clinicians list their own cash prices for a telehealth visit, and a GLP-1 prescription (Wegovy pen and pill, Zepbound, Ozempic, Mounjaro, Rybelsus, Foundayo) is something a clinician may write at that visit rather than a product Sesame itself dispenses. Individual clinician credentials — MD/NP/PA-C, specialty, rating, review count — are published per listing, which no other row in this module does.

Pricing: You are buying a visit, not a plan. Across ten states we swept, the new-patient telehealth visit runs $46–$50 — $46 in Texas and Arizona, $47 in Florida, Illinois and Montana, $49 in California, New York and Georgia, $50 in Wyoming and Alaska. The medication is billed separately by whoever fills it. The “$37” on Sesame's own landing page did not reproduce in any of the ten; it may be a Sesame Plus member rate, which we could not verify, and the lander does not qualify it.

Worth knowing: Because every clinician sets their own price, there is no single Sesame price and no single state list — availability is per-clinician licensure. Nothing here is a subscription, so nothing here is a weight-loss program either: no coaching, no ongoing plan, no medication pricing of Sesame's own. And its “anti-aging treatment” category is dermatology — online and in-person skin consults — so a reader who arrives from a longevity search lands on acne and eczema.

Found Health

GLP-1 & oral non-GLP-1 weight loss · 41 states

A weight-loss-only telehealth program with the strongest named clinical bench in this module — Dr. Rekha Kumar MD MS (former medical director of the American Board of Obesity Medicine), Dr. Jonathan Larson MD MBA, Dr. Judith Korner MD PhD of Columbia, Dr. Shebani Sethi MD of Stanford and Dr. Kyu Rhee MD MPP. Fourteen medications: compounded semaglutide, tirzepatide and liraglutide, the brand-name GLP-1s, oral Foundayo (orforglipron) and Rybelsus, and four oral non-GLP-1s — Contrave, metformin, topiramate and zonisamide.

Pricing: The Generics Plan (the oral non-GLP-1s) is $89/month with commercial insurance or $149/month cash, month to month; the compounded GLP-1 plan is $199 insurance or $299 cash. The widely quoted $49 needs both a twelve-month commitment and commercial insurance. Two traps in Found's own binding Offer Terms: billing is every four weeks, so it is thirteen cycles a year rather than twelve, and its “12 months” is defined as 48 weeks — about eleven calendar months of cover.

Worth knowing: Found's binding Offer Terms and its own /plans-and-pricing page disagree on three of four price cells for the compounded GLP-1 plan. It names no compounding pharmacy — though it does make a direct claim about who fills the prescription, stating on its compounded-semaglutide page that “Found partners exclusively with 503A-licensed pharmacies”, which is a commitment rather than the generic compliance sentence some operators offer in its place. Its 41-state list contradicts itself twice on one page — New Mexico renders an availability panel while being absent from the state selector, and California is in the accepted list while its own panel reads “No plans available for this state.” Membership is refundable only within three days or before the first consult; medications and lab kits are non-refundable once shipped, and renewals are non-refundable. And Found itself discloses that Dr. Kumar does not interact directly with patients.

Compounded-medication note. Compounded GLP-1 medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Prices shown are stated by each company and may change. Any decision to start, stop, or change a GLP-1 belongs with a licensed prescriber.

Advertising disclosure. Clearhead Lab may earn a commission if you start treatment through these links, at no extra cost to you. Everything linked here is a paid partner, listed because it pays us — the caveats printed beside each are what should decide it. See our disclosure.

A few gentle questions

Is brain fog a side effect of Ozempic?

Brain fog is not among the common adverse reactions listed for Ozempic. That does not identify the cause in an individual. If symptoms started or worsened after a dose change, discuss the timing and other medications with the prescriber.

Why do I feel foggy on Ozempic or Wegovy?

Eating less or losing fluid through vomiting or diarrhea may contribute. Low blood sugar is especially important to consider if you also take insulin or a sulfonylurea. Your prescriber can help you sort out the possibilities.

Does Ozempic protect your brain or cause dementia?

Neither is proven. GLP-1 drugs reduce neuroinflammation in lab studies and were a leading hope for protecting against Alzheimer's — but the first large dedicated trial (EVOKE) found oral semaglutide did not slow cognitive or functional decline in early Alzheimer's. So the protective claim is plausible but unproven, and there's no evidence the drug causes dementia. The honest stance: don't credit or blame the molecule beyond what the evidence supports.

How do I fix brain fog from a GLP-1 medication?

Keep a record of when it happens and discuss it with the prescriber. Mention any changes in eating, drinking, vomiting, diarrhea, or glucose readings if you monitor them. Seek prompt care for severe symptoms.

Where this comes from

  1. Choudhury A, et al. (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis.. Clinical Therapeutics. https://pubmed.ncbi.nlm.nih.gov/41862354/
  2. Kackley ML, Buga A, Crabtree CD, et al. (2022). The effects of a 6-week controlled, hypocaloric ketogenic diet, with and without exogenous ketone salts, on cognitive performance and mood states in overweight and obese adults.. Frontiers in Neuroscience. https://pubmed.ncbi.nlm.nih.gov/36248655/
  3. McLaren C, et al. (2025). A Secondary Analysis of Caloric Restriction and Exercise Effects on Cognitive Function in Functionally Limited Postmenopausal Women with Overweight or Obesity.. Nutrients. https://pubmed.ncbi.nlm.nih.gov/40647181/
  4. Pross N (2017). Effects of Dehydration on Brain Functioning: A Life-Span Perspective.. Annals of Nutrition & Metabolism. https://pubmed.ncbi.nlm.nih.gov/28614811/
  5. Ganio MS, Armstrong LE, Casa DJ, et al. (2011). Mild dehydration impairs cognitive performance and mood of men.. British Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/21736786/
  6. Warren RE, Frier BM (2005). Hypoglycaemia and cognitive function.. Diabetes, Obesity & Metabolism. https://pubmed.ncbi.nlm.nih.gov/16050942/
  7. Evola G, et al. (2026). Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.. Inflammation Research. https://pubmed.ncbi.nlm.nih.gov/41504939/
  8. Corcoran C, et al. (2026). The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.. Molecular and Cellular Neurosciences. https://pubmed.ncbi.nlm.nih.gov/42014236/
  9. Gandhi H, et al. (2025). GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.. Frontiers in Endocrinology. https://pubmed.ncbi.nlm.nih.gov/41356006/
  10. Cummings JL, et al. (2026). Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.. Neurodegenerative Disease Management. https://pubmed.ncbi.nlm.nih.gov/42159155/
  11. US Food and Drug Administration (2026). Ozempic (semaglutide) injection prescribing information.. Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.